Research Studies at the Lugene Eye Institute

Acucela

  • An investigator-masked, dose-escalation study to determine the safety, tolerability, pharmacokinetics, and efficacy of XXX ophthalmic solution in subjects with primary open angle glaucoma or ocular hypertension (2011)
  • A Phase 3 Study to determine the efficacy, and safety of XXX in subjects with Dry Eye Syndrome (2012)

Allergan

  • A 6-day, phase 3, multicenter, randomized, double-masked, parallel study to compare the safety and efficacy of XXX 0.5 ophthalmic solution with that of vehicle in the treatment of acute bacterial conjunctivitis (2007)
  • A multicenter, randomized, double-masked, parallel-group study to evaluate the safety and efficacy of XXX ophthalmic emulsion 0.05% (XXX) administered 4 times daily for 16 weeks in patients with primary pterygium (2007)
  • Ophthalmic AGN-195263 for the treatment of meibomian gland dysfunction (2012)
  • Evaluation of bimatoprost 0.01% and bimatoprost 0.03% in patients with glaucoma or ocular hypertension (2013)

Alcon

  • An evaluation of the safety and efficacy of XXX ophthalmic solution 0.5% for treatment of bacterial conjunctivitis in the USA (2008)
  • A randomized double-masked study of XXX XX 0.25% (XXX) versus vehicle in dry eye patients (2009)
  • An evaluation of the efficacy and safety of XXX ophthalmic solution for the treatment of adenoviral conjunctivitis (2009)
  • A randomized, double-masked study of XXX 0.05% ophthalmic solution and XXX 0.10% ophthalmic solution versus XXX vehicle in the treatment of dry eye (2009)

Altheos

  • A phase 1/2a randomized, investigator-masked, placebo and active-controlled, dose-ranging study of the safety and efficacy of XXX in subjects with primary open angle glaucoma (POAG) and ocular hypertension (2012)

Bausch & Lomb

  • A randomized, multicenter, double-masked, parallel-group clinical safety and efficacy evaluation of XXX etabonate ophthalmic gel, 0.5% versus vehicle for the treatment of inflammation and pain following cataract surgery (2008)
  • A clinical safety and efficacy evaluation of XXX (XXX 0.5% and XXX 0.3% ophthalmic suspension) compared to XXX (XXX ophthalmic suspension 0.5%), XXX ophthalmic solution USP, 0.3%, and the vehicle of XXX for the treatment of blepharoconjunctivitis in pediatric subjects (2008)
  • A randomized, double-masked, parallel-group, vehicle-controlled, multicenter, exploratory study assessing safety and efficacy of XXX ophthalmic suspension in dry eye syndrome (2010)
  • A randomized, double-masked, parallel-group, dose-finding Study Comparing
  • the Safety and Efficacy of xxx (0.006%, 0.012%, 0.024% and 0.040%) to XXX 0.005% in subjects with open angle glaucoma or ocular hypertension (2010)
  • A study to evaluate the safety of XXX (XXX ophthalmic suspension) 0.6% compared to vehicle following TID dosing for 7 Days (2010)
  • A randomized, double-masked, active-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of topical (XXX) ophthalmic suspension compared with gatifloxacin 0.3% ophthalmic solution for the treatment of presumed bacterial conjunctivitis in subjects from birth to 31 days of age (2012)
  • A randomized, multicenter, double-masked, parallelgroup study comparing the safety and efficacy of (study drug) ophthalmic solution with timolol maleate ophthalmic solution 0.5% in subjects with open-angle glaucoma or ocular hypertension (2013)

Bayer

  • Prospective case crossover study to assess whether XXX exposure in men with erectile dysfunction increases the risk for the development of non-arthritic anterior ischemic optic meuropathy (NAION) (2009)

Innopharma, Inc.

  • A multi-center, double-masked, randomized, parallel assignment study to determine the therapeutic equivalence of XXX 1% ophthalmic suspension manufactured by Innopharma, Inc. with respect to Azopt ™ in patients with primary open-angle glaucoma or ocular hypertension

Inotek

  • A Phase I/II multi-center, randomized, double-masked, placebo-controlled, dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics (efficacy) of chronic twice-daily topical monocular application of XXX ophthalmic formulation in adults with ocular hypertension or primary open-angle glaucoma (2010)

Insite Vision

  • A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of XXX (1.0% XXX and 0.1% XXX) compared to XXX alone, XXX 0.1% alone, and vehicle in the treatment of subjects with nonbacterial blepharitis (2011)

ISTA

  • Efficacy and safety of XXX ophthalmic solution QD vs. placebo QD for treatment of ocular inflammation and pain associated with cataract surgery (2009)
  • A dose-ranging study to evaluate the safety and efficacy of XXX ophthalmic solution versus placebo in alleviating the signs and symptoms of dry eye disease (2010)

Novabay

  • A multicenter, randomized study of the efficacy and safety of (XXX) ophthalmic solution for the treatment of adenoviral conjunctivitis (2012)
  • A multicenter, randomized study of the efficacy and safety of (study drug) ophthalmic solution 0.3% for the treatment of bacterial conjunctivitis (2013)

Novagali

  • A multicenter, randomized, double-masked, 3 parallel arms placebo-controlled study to assess the efficacy and safety of (study drug) emulsion administered in pediatric patients with active severe vernal keratoconjunctivitis with severe keratitis (2013)

SunPharma

  • Comparison of the efficacy and safety of XXX, XXX 0.005% ophthalmic solution (test) and XXX (XXX0.005% ophthalmic solution-reference) when administered once daily in subjects with open angle glaucoma or ocular hypertension: A Clinical Equivalence Study (2010)
  • A clinical evaluation of safety of XXX's XXX 0.005% ophthalmic solution when administered once daily in subjects with open angle Glaucoma or ocular hypertension: An Open Label Extension Study (2010)

If you are interested in participating in a clinical trial, please click here to inquire about any of our current open studies. You can also contact our research department at (818) 246-2560.

1510 South Central Avenue
Suite 300
Glendale, CA 91204
(818) 265-2255

Lugene Eye Institute- Glendale Ophthalmologist
Website: www.lugeneeye.com © 2019 All Rights Reserved.